Literature DB >> 20800308

Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice.

Gareth Morris-Stiff, Ariel E Feldstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20800308     DOI： 10.1016/j.jhep.2010.07.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  12 in total

1.  Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage.

Authors:  Cosimo Giannini; Ariel E Feldstein; Nicola Santoro; Grace Kim; Romy Kursawe; Bridget Pierpont; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2013-04-26       Impact factor: 5.958

2.  Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet.

Authors:  Joel R Garbow; Jason M Doherty; Rebecca C Schugar; Sarah Travers; Mary L Weber; Anna E Wentz; Nkiruka Ezenwajiaku; David G Cotter; Elizabeth M Brunt; Peter A Crawford
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-31       Impact factor: 4.052

3.  Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice.

Authors:  João Paulo G Camporez; François R Jornayvaz; Max C Petersen; Dominik Pesta; Blas A Guigni; Julie Serr; Dongyan Zhang; Mario Kahn; Varman T Samuel; Michael J Jurczak; Gerald I Shulman
Journal:  Endocrinology       Date:  2013-06-13       Impact factor: 4.736

4.  FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology.

Authors:  Yusuke Murata; Morichika Konishi; Nobuyuki Itoh
Journal:  J Nutr Metab       Date:  2011-02-06

5.  Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study.

Authors:  Hongmei Yan; Mingfeng Xia; Xinxia Chang; Qiong Xu; Hua Bian; Mengsu Zeng; Shengxiang Rao; Xiuzhong Yao; Yinfang Tu; Weiping Jia; Xin Gao
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

Review 6.  Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.

Authors:  Md Ashraful Alam; Riaz Uddin; Nusrat Subhan; Md Mahbubur Rahman; Preeti Jain; Hasan Mahmud Reza
Journal:  J Lipids       Date:  2015-01-12

Review 7.  Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies.

Authors:  Christophe Kosinski; François R Jornayvaz
Journal:  Nutrients       Date:  2017-05-19       Impact factor: 5.717

8.  Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Anna Alisi; Sara Ceccarelli; Nadia Panera; Federica Prono; Stefania Petrini; Cristiano De Stefanis; Marco Pezzullo; Alberto Tozzi; Alberto Villani; Giorgio Bedogni; Valerio Nobili
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

9.  Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice.

Authors:  Yongmei Yu; Xian H Zhang; Blake Ebersole; David Ribnicky; Zhong Q Wang
Journal:  Sci Rep       Date:  2013-11-05       Impact factor: 4.379

10.  Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children.

Authors:  Man-Chin Hua; Jing-Long Huang; Ching-Chih Hu; Tsung-Chieh Yao; Ming-Wei Lai
Journal:  Front Pediatr       Date:  2019-10-30       Impact factor: 3.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.